Effect of Celecoxib on Perioperative Inflammatory Response in Colon Cancer

Not Recruiting

Trial ID: NCT01284504


The proposed study aims to investigate how the administration of a drug known to reduce inflammation in humans, Celecoxib, will effect the peri-operative inflammatory response of a patient undergoing primary tumor resection surgery for colon cancer. The proposed project is an exploratory study, and will use data from blood samples and tumor samples to attempt to elucidate the immune and inflammatory response in colon cancer patients undergoing primary resection of their tumors.

Official Title

The Effect Of Celecoxib On The Perioperative Inflammatory Response In Colon Cancer Patients - A Double-Blind Placebo-Controlled Trial

Stanford Investigator(s)

Andrew A. Shelton, MD, FACS, FACRS
Andrew A. Shelton, MD, FACS, FACRS

Clinical Professor, Surgery - General Surgery


Inclusion Criteria:

- Colon cancer patients with no evidence of metastasis in distant organs (i.e., TNM stage
I-III), who are

   - between 18 and 75 years old,

   - have a body mass index (BMI) between 18 and 35 kg/m^2,

   - and are eligible for laparoscopically-assisted colectomy for primary tumor resection.

   - Patients must have the ability to understand and the willingness to sign a written
   informed consent document.

Exclusion Criteria:

- A history of allergic-type reactions to celecoxib or sulphonamides,

   - a history of asthma, skin reactions or other allergic reactions to aspirin or other

   - a history of thromboembolic event (cerebrovascular accident, transient ischemic

   - unstable angina, myocardial infarction, deep vein thrombosis, or pulmonary embolism),

   - renal insufficiency (defined by a serum creatinine level > 1.5 mg/dL or blood urea
   nitrogen level > 22 mg/dL),

   - active gastrointestinal bleeding in the 60 days before surgery,

   - alcohol or drug abuse, and

   - previous chemotherapy or abdominal/pelvic radiation therapy.

   - After randomization, other exclusion criteria will include a surgical procedure longer
   than 6 h, inability to extubate the trachea within 4 h after operation, evidence of a
   new postoperative myocardial infarction, abnormal postoperative mental status or any
   new neurologic deficit, significant postoperative bleeding (with a hemoglobin level <
   7.5 g/dL), requiring blood transfusion, or a urine output of less than 30 mL/h.


drug: Celecoxib

other: placebo

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Julia McNeal

New Trial Alerts